The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 3, 2015, Pages 265-271

  Roviello, Giandomenico ^a   Petrioli, Roberto ^a   Laera, Letizia ^a   Francini, Edoardo ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

Author keywords

Abiraterone acetate; Cabazitaxel; Enzalutamide; Prostate cancer; Sequential therapy

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; CABOZANTINIB; DOCETAXEL; ENZALUTAMIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PHENYLTHIOHYDANTOIN; TAXOID;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; VISCERAL METASTASIS; ANALOGS AND DERIVATIVES; MALE; METASTASIS; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ABIRATERONE ACETATE; HUMANS; MALE; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 84938199873     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.04.010     Document Type: Review

References (40)

1. de Bono J.S., Oudard S., Ozguroglu M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
2. de Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
3. Scher H.I., Fizazi K., Saad F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197. AFFIRM Investigators.
4. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(Jul (5)):411-422. IMPACT Study Investigators. 10.1056/NEJMoa1001294.
5. Parker C., Nilsson S., Heinrich D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369:213-223.
6. Fizazi K., Scher H.I., Molina A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13:983-992. COU-AA-301 Investigators.
7. Noonan K.L., North S., Bitting R.L., Armstrong A.J., Ellard S.L., Chi K.N. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013, 24(Jul):1802-1807.
8. Loriot Y., Bianchini D., Ileana E., et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013, 24(Jul):1807-1812.
9. Wissing M.D., Coenen J.L., van den Berg P., et al. A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Int J Cancer 2015, 136(March (6)):E760-E772.
10. Pezaro C.J., Omlin A.G., Altavilla A., et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol 2013 Dec 17, (pii S0302-2838(13)01308-0). 10.1016/j.eururo.2013.11.044.
11. Al Nakouzi N., Le Moulec S., Albigès L., et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014, (May). (pii S0302-2838(14)00396-0). 10.1016/j.eururo.2014.04.015.
12. Sella A., Sella T., Peer A., et al. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2014, (Jun). (pii S1558-7673(14)00110-4). 10.1016/j.clgc.2014.06.007.
13. Schrader A.J., Boegemann M., Ohlmann C.H., et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014, 65(1):30-36. (Epub 2013 Jul 2). 10.1016/j.eururo.2013.06.042.
14. Bianchini D., Lorente D., Rodriguez-Vida A., et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014, 50(1):78-84. (Epub 2013 Sep 25). 10.1016/j.ejca.2013.08.020.
15. Thomsen F.B., Røder M.A., Rathenborg P., Brasso K., Borre M., Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol 2013, 48(Jun (3)):268-275. (Epub 2013 Nov 21). 10.3109/21681805.2013.860189.
16. Badrising S., van der Noort V., van Oort I.M., et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014, 120(Apr (7)):968-975. (Epub 2013 Dec 30). 10.1002/cncr.28518.
17. Schmid S.C., Geith A., Böker A., et al. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Adv Ther 2014, 31(2):234-241. (Epub 2014 Jan 18). 10.1007/s12325-014-0092-1.
18. Brasso K., Thomsen F.B., Schrader A.J., et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol 2014, (August). pii: S0302-2838(14)00680-0.
19. Francini E., Petrioli R., Roviello G. No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. Expert Rev Anticancer Ther 2014, 14(October (10)):1135-1140.
20. Li Y., Chan S.C., Brand L.J., Hwang T.H., et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res 2013, 73:483-489.
21. Antonarakis E.S., Lu C., Wang H., Luber B., et al. Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014, 32:5. (suppl; abstr 5001).
22. Carver B.S., Chapinski C., Wongvipat J., Hieronymus H., et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19(5):575-586.
23. Sahu B., Laakso M., Pihlajamaa P., et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res 2013, 73(5):1570-1580.
24. Richards J., Lim A.C., Hay C.W., et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012, 72(9):2176-2182.
25. van Soest R.J., van Royen M.E., de Morree E.S., et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013, 49:3821-3830.
26. Francini E., Roviello G. How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue. Tumour Biol 2014, 35(August (8)):7391-7392.
27. Francini E., Fiaschi A.I., Petrioli R., et al. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer. Anticancer Drugs 2014, 25(4):472-477.
28. Caffo O., De Giorgi U., Fratino L., et al. Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: results of an Italian multicentre study. Eur Urol 2014, (Oct). (pii: S0302-2838(14)01022-7).
29. Collette L., Burzykowski T., Schroder F.H. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006, 42:1344-1350.
30. Caffo O., Veccia A., Maines F., Bonetta A., Spizzo G., Galligioni E. Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. Future Oncol 2014, 10(May (6)):985-993. 10.2217/fon.14.24.
31. Schnadig I.D., Bhor M., Vogelzang N.J. Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatsic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2013, 31(Suppl. 6). (abstract 79).
32. Angelergues A., Maillet D., Flechon A., et al. Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: sequencing might matter. J Clin Oncol 2013, 31(Suppl. 6). (abstract 5063).
33. Sonpavde G., Bhor M., Hennessy D., et al. Outcomes with different sequence of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration resistant prostate cancer. Proceedings of the European Society For Medical Oncology (ESMO'13) 2013, (Abstract 2905).
34. Ryan C.J., Smith M.R., de Bono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
35. Beer T.M., Armstrong A.J., Rathkopf D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014, 371(July (5)):424-433. the PREVAIL Investigators.
36. Suzman D.L., Luber B., Schweizer M.T., Nadal R., Antonarakis E.S. Clinical activity of enzalutamide vs. docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 2014, (Jul). [Epub ahead of print]. 10.1002/pros.22844.
37. You W.K., McDonald D.M. The hepatocyte growth factor/c-Met signalling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep 2008, 41:833-839.
38. Smith D.C., Smith M.R., Sweeney C., et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2012, 31(4):412-419.
39. Smith M.R., Sweeney C.J., Corn P.G., et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 2014, 32(Oct (30)):3391-3399. (Epub 2014 Sep 15). 10.1200/JCO.2013.54.5954.
40. Buonerba C., Federico P., Bosso D., et al. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. Future Oncol 2014, 10(Jun (8)):1353-1360. 10.2217/fon.14.71.